Viewing nowCombinationCrestor-Candeza Tablet 10/8 mg
Rosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.

MFDS item code 202008724 · Approved 2020.12.11 · Insurance code 649105120
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk
This medication is used for patients who require simultaneous administration of two drugs, candesartan cilexetil and rosuvastatin. Candesartan cilexetil is primarily used for patients with essential hypertension and heart failure with reduced left ventricular function when there is a need for additional ACE inhibitors or when intolerable. Rosuvastatin is used for various types of dyslipidemia that are difficult to control with diet and exercise, especially for patients with primary hypercholesterolemia or familial hypercholesterolemia. Additionally, rosuvastatin helps to lower total cholesterol and LDL-cholesterol, delaying the progression of atherosclerosis and reducing the risk of stroke, myocardial infarction, and arterial revascularization procedures in patients with elevated high-sensitivity C-reactive protein and cardiovascular disease risk factors. Therefore, this medication is used to manage both hypertension and hyperlipidemia simultaneously and improve cardiovascular disease risk.
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. Candesartan cilexetil — Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at increased risk of hypotension, such as those with volume depletion. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. Candesartan cilexetil — Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or longer, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. Rosuvastatin — Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. Elderly patients: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Candesartan cilexetil — Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Candesartan cilexetil — Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with a history of allergies to this medication, liver disease, severe kidney impairment, or hereditary angioedema should not take it. Women of childbearing potential should take appropriate contraceptive measures considering the possibility of pregnancy, and this medication should not be used if planning pregnancy or during pregnancy. Caution should be exercised when administering to elderly patients, patients with hyperkalemia, and those with liver impairment. Regular monitoring of liver function tests and serum potassium levels is necessary. This medication can cause muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis. Patients experiencing unusual muscle symptoms should contact their physician immediately. As this medication may affect liver function, liver enzyme levels should be monitored periodically, and if liver function is severely impaired, discontinuation is necessary. This medication may interact with other drugs, so inform your physician or pharmacist about any other medications being taken. Nursing mothers are advised not to take this medication, and if necessary, should discontinue breastfeeding. In case of overdose, symptoms such as hypotension and dizziness may occur, and immediate medical assistance should be sought. Use caution while driving or operating machinery, as transient dizziness may occur during treatment. This medication should be kept out of reach of children and stored in its original container to maintain quality.
Headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, nausea, increased blood glucose, decreased blood sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, tooth extraction, orthostatic dizziness, molluscum contagiosum, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, increased blood pressure, orthostatic hypotension, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, productive cough, idiopathic pulmonary fibrosis, worsening hypertension, unstable blood pressure, dizziness, positional vertigo, adrenal insufficiency, leukopenia, neutropenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, diaphoresis, hand tremors, decreased concentration, convulsions, altered consciousness, dizziness, headache, intestinal vascular edema, diarrhea, increased liver enzyme levels, hepatitis, elevated AST, elevated ALT, elevated γ-GTP, jaundice, rash, urticaria, angioedema, myalgia, weakness, increased creatine kinase, elevated serum myoglobin, elevated urinary myoglobin, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorders, decreased libido, forgetfulness, decreased appetite, increased appetite, tinnitus, ageusia, erectile dysfunction, constipation, abdominal pain, pancreatitis, rash, urticaria, myopathy, rhabdomyolysis, weakness, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, thrombocytopenia, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular muscle weakness
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The storage temperature should be kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
Pink round film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
AlboGen Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.